Where there's a web, there's a way: Commercial genetic testing and the Internet

Community Genetics

Volumn 6, Issue 1, 2003, Pages 46-57

  Williams Jones, Bryn ^a,b  

^a HOMERTON COLLEGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Canada; Direct to consumer; Ethics; Genetic testing; Health care services; Internet; Policy; Private purchase

Indexed keywords

ARTICLE; CONSUMER; ETHICS; GENETIC ANALYSIS; GENETIC PROCEDURES; HEALTH CARE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH PRACTITIONER; HUMAN; INTERNET; POLICY; PRIORITY JOURNAL; SOCIAL ASPECT;

GENETICS AND REPRODUCTION;

GENETIC COUNSELING; GENETIC PRIVACY; GENETIC SCREENING; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERNET;

EID: 0037942643     PISSN: 14222795     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069538     Document Type: Article

References (92)

1. WHO Programme in Human Genetics: Proposed International Guidelines on Ethical Issues in Medical Genetics. Geneva, 1998, online: http://www.who.int/ncd/hgn/hgnethic.htm (accessed: 28 November 2002).
2. Williams-Jones B: Re-framing the discussion: Commercial genetic testing in Canada. Health Law J 1999;7:49-68.
3. Myriad Genetics: Myriad Genetics launches predictive medicine business in the United Kingdom and Ireland. Press Release 8 March 2000, online: http://www.myriad.com/pr/20000308.html (accessed: 15 November 2002).
4. Myriad Genetics: Myriad Genetics launches molecular diagnostic testing in Canada - MDS Laboratory Services to provide BRACAnalysis throughout Canada. Press Release 9 March 2000, online: http://www.myriad.com/pr/20000309.html (accessed: 15 November 2002).
5. Myriad Genetics: Myriad Genetics launches genetic testing in Japan - Falco Biosystems, Ltd. to promote Myriad's commercial products in Japan. Press Release 1 February 2000, online: http://www.myriad.com/pr/20000201.html (accessed: 15 November 2002).
6. Myriad Genetics: Myriad Genetics launches predictive medicine testing in Germany, Switzerland, and Austria. Press Release 27 June 2001, online: http://www.myriad.com/pr/20010627.html (accessed: 15 November 2002).
7. Mazankowski D: A Framework for reform: Report of the Premier's Advisory Council on Health. Edmonton, AB, December 2001, online: http://www.gov.ab.ca/home/health_first/documents/PACH_report.pdf (accessed: 15 November 2002).
8. Romanow RJ: Final Report: Building on Values: The Future of Health Care in Canada. Ottawa, ON, 28 November 2002, online: http://www.healthcarecommission.ca/ (accessed 6 March 2003).
9. Statistics Canada: Household Internet Use Survey. Ottawa, 2000.
10. Fox S, Rainie L: The Online Health Care Revolution: How the Web Helps Americans Take Care of Themselves. Washington, 26 November 2000, online: http://www.pewinternet.org/reports/toc.asp?Report=26 (accessed: 15 November 2002).
11. Qaadri S: The best prescription: Surf with caution. The Globe and Mail, 19 February 2002;R5.
12. Huggins C: For gene info, patients visit Web before doctor. Reuters, 23 August 2001.
13. Sastry S, Carroll P: Doctors, patients and the Internet: Time to grasp the nettle. Clin Med 2002;2:131-133.
14. Baker DB: Patient-centered healthcare: The role of the internet. Dis Manage Health Outcomes 2001;9:411-420.
15. Pines WL: A history and perspective on direct-to-consumer promotion. Food Drug Law J 1999;54:489-518.
16. Mintzes B, Barer ML, Kravitz RL, Kazanjian A, Bassett K, Lexchin J, Evans RG, Pan R, Marion SA: Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: Two-site cross-sectional survey. B Med J 2002;324:278-279.
17. Taylor MRG, Alman A, Manchester DK: Use of the Internet by patients and their families to obtain genetics-related information. Mayo Clin Proc 2001;76:772-776.
18. Ellison J, Earl L, Ogg S: Internet Shopping in Canada. Ottawa, Statistics Canada, February 2001.
19. Peterson G: Electronic Commerce and Technology Use. Ottawa, Statistics Canada, September 2001, online: http://www.statcan.ca/cgi-bin/downpub/listpub.cgi?catno=56F0004MIE2001005 (accessed: 15 November 2002).
20. O'Reilly M: Get ready for online sales of prescription drugs. Can Med Assoc J 1999;161:557.
21. Holtzman NA, Shapiro D: The new genetics: Genetic testing and public policy. Br Med J 1998;316:852-856.
22. Burgess MM: Marketing and fear-mongering: Is it time for commercialized genetic testing?; in Caulfield TA, Williams-Jones B (eds): The Commercialization of Genetics Research: Ethical, Legal, and Policy Issues. New York, Kluwer Academic/Plenum Publishers, 1999, pp 181-194.
23. Caulfield TA, Burgess MM, Williams-Jones B, with, Baily M-A, Chadwick R, Cho M, Deber R, Fleising U, Flood CM, Friedman J, Lank R, Owen T, Sproule J: Providing genetic testing through the private sector: A view from Canada. ISUMA. Can J Policy Res 2001;2:72-81.
24. Gollust SE, Hull SC, Wilfond BS: 'Bringing you the world of genetics': Direct-to-consumer genetic services on the internet. American Society of Human Genetics 52nd Annual Meeting, Baltimore, October, 2002, online: http://www.faseb.org/genetics/ashg02s/f40.htm (accessed: 15 November 2002).
25. Quest Diagnostics: Quest Diagnostics announces national agreement with Aetna US Healthcare. Press Release 27 March 2000, online: http://www.questdiagnostics.com/brand/company/news/b_comp_news_032700.html (accessed: 15 November 2002).
26. Myriad Genetics: Myriad Genetics and Lab-Corp form exclusive predictive medicine marketing alliance. Press Release, 4 December 2001, online: http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker= mygn&script=410&layout=9&item_id=232709 (accessed: 15 November 2002).
27. Myriad Genetics: Aetna US Healthcare and Myriad Genetics distribute American Medical Association monograph to educate physicians on genetic testing. Press Release, 20 October 1999, online: http://www.myriad.com/pr/19991020.html (accessed: 12 November 2002).
28. Williams-Jones B, Graham J: Actor-network theory: A tool to support ethical analysis of commercial genetic testing. New Genetics and Society, in press.
29. Task Force on Genetic Information and Insurance: Genetic Information and Health Insurance: Report of the Task Force on Genetic Information and Health Insurance. Washington 1993, online: http://www.ornl.gov/TechResources/Human_Genome/publicat/ hgn/v4n1/06insure.html (accessed: 15 November 2002).
30. Lemmens T, Bahamin P: Genetics in life, disability and additional health insurance in Canada: A comparative legal and ethical analysis; in Knoppers BM (ed): Socio-Ethical Issues in Human Genetics. Cowansville, Éditions Yvon Blais, 1998, pp 115-275.
31. Hall MA, Rich SS: Laws restricting health insurers' use of genetic information: Impact on genetic discrimination. Am J Hum Genet 2000;66:293-307.
32. MacDonald C, Williams-Jones B: Ethics and genetics: Susceptibility testing in the work-place. J Bus Ethics 2002;35:235-241.
33. Bosompra K, Ashikaga T, Flynn BS, Worden JK, Solomon LJ: Psychosocial factors associated with the public's willingness to pay for genetic testing for cancer risk: A structural equations model. Health Educ Res 2001;16:157-172.
34. Burgess MM, Hayden MR: Patients' rights to laboratory data: Trinucleotide repeat length in Huntington disease. Am J Med Genet 1996;62:6-9.
35. Cox SM, McKellin W: 'There's this thing in our family': Predictive testing and the construction of risk for Huntington disease. Sociol Health Illness 1999;21:622-646.
36. Hofmann W, Schlag PM: BRCA1 and BRCA2: Breast cancer susceptibility genes (review). J Cancer Res Clin Oncol 2000;126:487-496.
37. Birmingham K: News: Myriad's rationale for wider testing. Nat Med 1997;3:709.
38. Smith O: News: Breast cancer susceptibility tests still valid, companies argue. Nat Med 1997;3:709.
39. Wired News Report: Hacker Posts Credit Card Info. Wired 10 January 2000, online: http://www.wired.com/news/technology/0,1282,33539,00.html (accessed: 15 November 2002).
40. Sullivan B: Today's privacy policies don't protect e-shoppers, advocate charges. Computer-World, 2001, online: http://www.computer-world.com/securitytopics/security/ privacy/story/0,10801,59928,00.html (accessed: 15 November 2002).
41. Yamey G: Eli Lilly violates patients' privacy (news). Br Med J 2001;323:65.
42. McKenna A: Playing fair with consumer privacy in the global on-line environment. Inform Commun Technol Law 2001;10:339-354.
43. Graber MA: Surf's up! Protecting the privacy of health information on the Internet. West J Med 2002;176:79-81.
44. Thurston WE, Burgess MM, Adair CE: Ethical issues in the use of computerized databases for epidemiologic and other health research (commentary). Chron Dis Canada 1999;20:127-131, online: http://www.hc-sc.gc.ca/hpb/lcdc/publicat/cdic/cdic203/cd203d_e.html (accessed: 15 November 2002.
45. Nielsen L: The Icelandic health sector database: Legal and ethical considerations; in Caulfield TA, Williams-Jones B (eds): The Commercialization of Genetic Research: Ethical, Legal, and Policy Implications. New York, Kluwer Academic/Plenum Press, 1999, pp 111-128.
46. Specter M: Decoding Iceland. The New Yorker, 1999, pp 40-51.
47. Frank L: Estonia prepares for national DNA database (news). Science 2000;290:31.
48. Knoppers BM, Caulfield TA, Kinsella TD: Legal Rights and Human Genetic Material. Toronto: Emond Montgomery Publications, 1996.
49. Maury MD, Kleiner DS: E-Commerce, ethical commerce? J Bus Ethics 2002;36:21-31.
50. Milunsky A: Commercialization of clinical genetic laboratory services: In whose best interests? (clinical commentary). Obstet Gynecol 1993;81:627-629.
51. Caulfield TA, Gold ER: Genetic testing, ethical concerns, and the role of patent law. Clin Genet 2000;57:370-375.
52. Secretary's Advisory Committee on Genetic Testing: Enhancing the Oversight of Genetic Tests: Recommendations of the SACGT. Bethesda, 2000, online: http://www4.od.nih.gov/oba/sacgt/reports/oversight_report.pdf (accessed: 12 November 2002).
53. Holtzman NA: Are genetic tests adequately regulated? Science 1999;286:409.
54. Coney S: Direct-to-consumer advertising of prescription pharmaceuticals: A consumer perspective from New Zealand. J Public Policy Market 2002;21:213-223.
55. Calfee JE: Public policy issues in direct-to-consumer advertising of prescription drugs. J Public Policy Market 2002;21:174-193.
56. Hancher L: Regulating drug promotion: The UK experience. J Consumer Policy 1987;10:383-407.
57. Mintzes B: The truth, the half truth, and nothing like the truth: Regulation and drug promotion in Canada; in Barer ML, McGrail KM, Cardiff K, Wood L, Green CJ (eds): Tales from the Other Drug Wars. Vancouver, Centre for Health Services and Policy Research, UBC, 2000, pp 59-69.
58. Reichertz PS: Legal issues concerning the promotion of pharmaceutical products on the internet to consumers. Food Drug Law J 1996;51:355-365.
59. Gollust SE, Hull SC, Wilfond BS: Limitations of direct-to-consumer advertising for clinical genetic testing. JAMA 2002;288:1762-1767.
60. Lynch HT, Lynch JF, Rubinstein WS: Prophylactic mastectomy: Obstacles and benefits (editorial). J Natl Cancer Inst 2001;93:1586-1587.
61. King M-C, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. JAMA 2001;286:2251-2256.
62. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-1615.
63. Carter RF: BRCA1, BRCA2 and breast cancer: A concise clinical review. Clin Invest Med 2001;24:147-157.
64. Baird PA: Genes, health and science policy: Genetic technologies and achieving health for populations. Int J Health Serv 2000;30:407-424.
65. Vineis P, Schulte P, McMichael AJ: Misconception about the use of genetic tests in populations. Lancet 2001;357:709-712.
66. Provincial Advisory Committee on New Predictive Genetic Technologies: Genetic Services in Ontario: Mapping the Future. Toronto, 30 November, 2001, online: http://www.gov.on.ca/health/english/pub/ministry/ geneticsrep01/genetic_report.pdf (accessed: 15 November 2002).
67. Human Genetics Commission: The Supply of Genetic Tests Direct to the Public: A Consultation Document. London, July 2002, online: http://www.hgc.gov.uk/testingconsultation/ (accessed: 15 November 2002).
68. Harper PS: Direct marketing of cystic fibrosis carrier screening: Commercial push or population need? J Med Genet 1995;32:249-250.
69. Hull SC, Prasad K: Reading between the lines: Direct-to-consumer advertising of genetic testing in the USA. Reproductive Health Matters 2001;9:44-48.
70. Evans JP, Skrzynia C, Burke W: The complexities of predictive testing. Br Med J 2001;322:1052-1056.
71. Emery J, Hayflick S: The challenge of integrating genetic medicine into primary care. Br Med J 2001;322:1027-1030.
72. Codori A-M: Psychological opportunities and hazards in predictive genetic testing for cancer risk. Colorectal neoplasia. II. Diagnosis and treatment. Gastroenterol Clin North Am 1997;26:19-39.
73. Burgess MM: Beyond consent: Ethical and social issues in genetic testing. Nat Rev Genet 2001;2:147-152.
74. Kinmonth AL, Reinhard J, Bobrow M, Pauker S: The new genetics: Implications for clinical services in Britain and the United States. Br Med J 1998;316:767-69.
75. Caulfield TA: Gene testing in the biotech century: Are physicians ready? (editorial). Can Med Assoc J 1999;161:1122-1124.
76. James CA, Geller G, Bernhardt B, Doksum T, Holtzman NA: Are practicing and future physicians prepared to obtain informed consent? The case of genetic testing for susceptibility to breast cancer. Commun Genet 1998;1:203-212.
77. Graham J: Harbinger of hope or commodity fetishism: 'Re-cognizing' dementia in an age of therapeutic agents. Int Psychogeriatr 2001;13:131-134.
78. MacDonald C: Commercialization of genetic services: The role of genetic counselors. Hum Reprod Genet Ethics 2002;8:1-3.
79. Williams-Jones B: History of a gene patent: Tracing the development and application of commercial BRCA testing. Health Law J, in press.
80. Murray J: Owning genes: Disputes involving DNA sequence patents. Chicago-Kent Law Rev 1999;75:231-257.
81. Harris M: Notes for remarks by Mike Harris, Ontario's premier. Ontario Advisory Committee on Predictive Genetic Technology, Toronto, 19 September, 2001.
82. Clement T: Speech Re: Myriad gene patent issue. Ontario Advisory Committee on Predictive Genetic Technology, Toronto, 19 September, 2001, online: http://www.gov.on.ca/health/english/news/speech/sp_091901_tc.html (accessed: 15 November 2002.
83. Canadian Cancer Society, National Cancer Institute of Canada: Canadian Cancer Society (CCS) and National Cancer Institute of Canada (NCIC) position on the patenting of BRCA1 and BRCA2 genes. Ottawa, 8 March 2002, online: http://www.cancer.ca/files/BRCApatents.pdf (accessed: 15 November 2002).
84. Ontario Ministry of Health and Long Term Care: Genetics and Gene Patenting: Charting New Territory in Health Care. Toronto, January 2002, online: http://www.gov.on.ca/health/english/pub/ministry/geneticsrep02/genetics.html (accessed: 15 November 2002).
85. Eggertson L: Ontario defies US firm's genetic patent, continues cancer screening. Can Med Assoc J 2002;166:494.
86. Canadian Press: Ontario defies US gene company over cancer test, arguing health care at risk. Excite News 19 September 2001, online: http://lists.essential.org/pipermail/ip-health/2001-September/001877.html (accessed: 15 November 2002).
87. Wadman M: Europe's patent rebellion. Fortune.com 1 October 2001, online: http://www.fortune.com (accessed: 15 November 2002).
88. Benowitz S: French challenge to BRCA1 patent underlies European discontent (news). J Natl Cancer Inst 2002;94:80-81.
89. Kent H: Patenting move ends BC's gene-testing program. Can Med Assoc J 2001;165:812-814.
90. British Columbia Ministry of Health Services: Federal leadership urged as genetic testing resumes. News Release, 14 February 2003, online: http://www2.news.gov.bc.ca/nrm_news_releases/2003HSER0009000160 (accessed: 6 March 2003).
91. Sheremeta L, Gold ER, Caulfield TA: Harmonizing commercialization and gene patent policy with other social goals. Proc 3rd Int DNA Sampling Conference, Montreal, 5-8 September, forthcoming.
92. Myriad Genetics: Myriad Genetics launches direct to consumer advertising campaign for breast cancer test. Press Release 12 September 2002, online: http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker= mygn&script=413&layout=9&item_id=333030 (accessed: 12 November 2002).